Project Grant R21DA061044
Award Date
5/1/25
Completion Date
4/30/27
Dollars Obligated
$231K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This $238,500 federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research investigating the effects of xylazine and opioids on inhibitory transmission in the prefrontal cortex. The key objectives are to: Test whether xylazine and opioids have synergistic effects on prefrontal cortex inhibitory transmission through distinct molecular mechanisms. Determine if xylazine and opioids inhibit...
This federal Project Grant award of $392,940 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research on the behavioral pharmacology of opioid and xylazine mixtures. The project aims to improve understanding of the interactions between opioids and xylazine, a non-opioid veterinary drug that has emerged as an adulterant contributing to the opioid crisis. The proposed studies will use well-established experimental methods...
This $387,750 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research on the molecular pharmacology of the drug xylazine and its relation to necrotizing skin lesions associated with chronic intravenous administration. The research project, to be conducted by Mercer University, will assess the binding affinity and functional effects of xylazine compared to other adrenergic receptor agonists...
This federal Project Grant award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a $408,486 community-based, longitudinal, mixed-methods study to investigate the growing crisis of xylazine exposure among people who use drugs (PWUD) in the Southeastern United States. The key objectives are to: 1) Employ community-based drug checking to determine xylazine's prevalence in the illicit drug supply; 2) Explore...
This $907,500 Project Grant awarded by the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to examine the impact of xylazine exposure on the risk of skin and soft tissue infections (SSTI) among people who inject drugs (PWID) in Lowell, Massachusetts. The key products and services to be delivered through this 2-year grant include: Prospectively recruiting and following 200 PWID to quantify their exposure to xylazine and other...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $237,750 to Temple University to conduct research on the effects of xylazine, a veterinary sedative, on methamphetamine-induced behavioral alterations in rats. The key objectives are to: (1) evaluate if xylazine enhances the acquisition and reinforcing efficacy of methamphetamine self-administration, (2) determine if xylazine exacerbates...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will provide $423,708 from September 30, 2024 to September 29, 2026 to the RU School of Osteopathic Medicine (RowanSOM) to conduct research on the cardiorespiratory and subjective effects of fentanyl-xylazine drug mixtures. The key objectives are to: 1) comprehensively characterize how xylazine impacts fentanyl-induced changes in heart rate, blood pressure,...
This $2,925,374 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to develop a novel reversal agent for treating overdoses from the combination of fentanyl and xylazine. The funded research will study a sequestrant compound that can simultaneously reduce levels of both fentanyl and the animal tranquilizer xylazine in the body, with the goal of restoring respiration and reversing sedation. The award...
This $266,742 federal Project Grant, awarded by the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs), will fund a two-year qualitative study to characterize transitions to low-frequency injecting and injection cessation among people using xylazine-adulterated fentanyl in Connecticut. The study aims to: 1) examine how exposure to xylazine-adulterated fentanyl intersects with social-structural influences to shape these transitions; 2) explore perceptions of...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support a 24-month mixed-methods study to examine the feasibility and acceptability of a Community-Based Drug Checking (CBDC) program operating through a Syringe Service Program (SSP) to detect the presence of xylazine in the illicit drug supply among rural and tribal communities in Minnesota. The $212,200 award to Research Triangle Institute...